# Edap TMS SA: overview

FOCL · Nasdaq · CIK 1041934 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/focl.md) · [Financials](/companies/focl/financials.md) · [Filings](/companies/focl/filings.md) · [Insiders](/companies/focl/insiders.md)

Latest reported revenue: [$13.2m](/filings/0001104659-26-097063.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-097063).

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.3](/filings/0001104659-26-057094.md) | [9.5](/filings/0001104659-26-097063.md) | [17.8](/filings/0001104659-26-057094.md) | [13.2](/filings/0001104659-26-097063.md) |
| Gross margin | % | [42.0%](/filings/0001104659-26-057094.md) | [51.1%](/filings/0001104659-26-097063.md) | [45.7%](/filings/0001104659-26-057094.md) | [55.6%](/filings/0001104659-26-097063.md) |
| Operating margin | % | [(44.2%)](/filings/0001104659-26-057094.md) | [(69.6%)](/filings/0001104659-26-097063.md) | [(41.4%)](/filings/0001104659-26-057094.md) | [(60.8%)](/filings/0001104659-26-097063.md) |
| Net margin | % | [(52.2%)](/filings/0001104659-26-057094.md) | [(67.4%)](/filings/0001104659-26-097063.md) | [(51.0%)](/filings/0001104659-26-057094.md) | [(109.7%)](/filings/0001104659-26-097063.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001104659-26-057094.md) | [(0.17)](/filings/0001104659-26-097063.md) | [(0.24)](/filings/0001104659-26-057094.md) | [(0.39)](/filings/0001104659-26-097063.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [41.6](/filings/0001558370-23-005629.md) | [44.1](/filings/0001558370-23-005629.md) | [55.1](/filings/0001558370-23-005629.md) | [69.4](/filings/0001104659-26-034528.md) | [70.5](/filings/0001104659-26-034528.md) |
| Gross margin | % | not reported | not reported | not reported | [41.4%](/filings/0001104659-26-034528.md) | [42.5%](/filings/0001104659-26-034528.md) |
| Operating margin | % | not reported | not reported | not reported | [(32.0%)](/filings/0001104659-26-034528.md) | [(35.0%)](/filings/0001104659-26-034528.md) |
| Net margin | % | not reported | not reported | not reported | [(29.7%)](/filings/0001104659-26-034528.md) | [(41.5%)](/filings/0001104659-26-034528.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [(0.55)](/filings/0001104659-26-034528.md) | [(0.78)](/filings/0001104659-26-034528.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/focl/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $37.9m | 7,309,254 |  | Unchanged |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $17.3m | 3,336,872 |  | Reduced −8,408 |
| [Rock Springs Capital Management LP](/funds/1595725.md) | 2026-06-30 | $7.2m | 1,386,000 |  | Added +8,000 |
| [FLAX POND CAPITAL, LLC](/funds/2106996.md) | 2026-06-30 | $3.8m | 736,230 |  | Reduced −47,216 |
| [FLAX POND CAPITAL, LLC](/funds/2106996.md) | 2026-06-30 | $2.9m | 789,446 |  | Added +6,000 |
| [Bruce & Co., Inc.](/funds/1358331.md) | 2026-06-30 | $2.3m | 438,652 |  | Unchanged |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $2.0m | 392,200 | Call | Added +311,400 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.4m | 271,500 | Call | Added +221,600 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $876.5k | 169,200 | Call | Added +96,600 |
| [Parkman Healthcare Partners LLC](/funds/1777015.md) | 2026-06-30 | $802.0k | 154,832 |  | Unchanged |

## Recent filings

[All 367 filings](/companies/focl/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-19 | 10:00 ET | [8-K](/filings/0001104659-26-098487.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-098487 |
| 2026-08-14 | 20:02 ET | [10-Q](/filings/0001104659-26-097063.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097063 |
| 2026-08-14 | 10:00 ET | [8-K](/filings/0001104659-26-096209.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-096209 |
| 2026-08-13 | 20:02 ET | [8-K](/filings/0001171843-26-005498.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005498 |
| 2026-08-11 | 21:04 ET | [8-K](/filings/0001104659-26-094134.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-094134 |
| 2026-06-26 | 20:05 ET | [8-K](/filings/0001171843-26-004324.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001171843-26-004324 |
| 2026-06-01 | 20:05 ET | [8-K](/filings/0001171843-26-003840.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-003840 |
| 2026-05-29 | 11:30 ET | [8-K](/filings/0001171843-26-003773.md) | 8.01 Other events | 0001171843-26-003773 |
| 2026-05-14 | 11:30 ET | [DEF 14A](/filings/0001104659-26-060700.md) | Proxy statement, period 2026-06-26 | 0001104659-26-060700 |
| 2026-05-07 | 20:03 ET | [10-Q](/filings/0001104659-26-057094.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057094 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034528.md), filed Mar 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e0664b41-75e7-4e0c-9b7d-5bc44e8a65f6)

## About the filer

- CIK: 1041934
- Tickers: FOCL
- Exchange: Nasdaq
- SIC code: 3845 Electromedical & Electrotherapeutic Apparatus
- State of incorporation: not reported
- Filer category: Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.